NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
0 hedge funds and large institutions have $0 invested in NRX Pharmaceuticals Warrant in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
6.58% less ownership
Funds ownership: 6.58% → 0% (-6.6%)
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $347 → $0 (-$347)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$347 |
NRXPW Hedge Fund Activity: Q2 2026 in Review
0 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2026, worth a combined $0 — down 100% from $347 a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NRXPW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Wolverine Asset Management, exiting entirely with an estimated $347 sold.
- 0 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2026, down from 2 in Q1 2026.
- Funds reported $0 of NRX Pharmaceuticals Warrant stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q2 2026 and 2 closed out, a net change of -2 holders.
- The largest NRX Pharmaceuticals Warrant seller in Q2 2026 was Wolverine Asset Management, an estimated $347 sold.
Based on aggregated 13F filings for Q2 2026.